All In Biotech

NDA 022577 · Gilead Sciences INC

Viread

Tenofovir Disoproxil Fumarate · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jan 18, 2012

Approved uses

6

Original approval plus efficacy supplements

Registered trials

1,145

277 Phase 3, 53 recruiting

FAERS reports

32,964

30,987 serious, 1,955 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B virus (HBV) have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely in HBV-infected patients who...

What it is approved for

From the label in effect Feb 18, 2025.

VIREAD is a nucleotide analog HIV-1 reverse transcriptase inhibitor and an HBV reverse transcriptase inhibitor and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. ( 1.1 ) for the treatment of chronic hepatitis B in adults and pediatric patients 2 years and older weighing at least 10 kg. ( 1.2 ) 1.1 HIV-1 Infection VIREAD is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. 1.2 Chronic Hepatitis B VIREAD is indicated for the treatment of chronic hepatitis B virus (HBV) in adults and pediatric patients 2 years of age and older weighing at least 10 kg .

Mechanism: Tenofovir disoproxil fumarate is an antiviral drug [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VIREAD · TENOFOVIR DISOPROXIL FUMARATE 40MG/SCOOPFUL · POWDER, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tenofovir Disoproxil" as an intervention, any sponsor and status, largest first.

All 1,145 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bone density decreased10,696
  • renal injury9,285
  • skeletal injury8,338
  • chronic kidney disease7,310
  • osteonecrosis7,271
  • bone loss7,084
  • multiple fractures6,842
  • renal failure6,700
  • osteoporosis5,420
  • tooth loss4,538
  • pain3,040
  • emotional distress2,861

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004578
2005639
2006526
2007566
2008530
2009573
2010473
2011556
2012495
2013530
2014932
20151,213
20161,209
20171,322
20181,506
20191,938
202012,186
20212,741
20221,734
20231,093
2024751
2025589
2026279

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Viread (Tenofovir Disoproxil Fumarate)

2024 spending

$2.9M

Beneficiaries

296

1,825 claims

Per beneficiary

$9,848

$38.91 per unit

View as table
YearSpending
2020$6,423,975
2021$4,643,114
2022$4,181,793
2023$3,626,217
2024$2,915,026

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 877 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.